Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study

Nicola Potere; Marcello Di Nisio; Donatella Cibelli; Rosa Scurti; Antonella Frattari; Ettore Porreca; Antonio Abbate; Giustino Parruti

doi:10.1136/annrheumdis-2020-218243

Article info

Letter

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study

Authors

Nicola Potere Department of Medical, Oral and Biotechnological Sciences, "G D'Annunzio" University, Chieti, Italy VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA PubMed articles Google scholar articles
Marcello Di Nisio Department of Medicine and Ageing Sciences, "G' D'Annunzio" University, Chieti-Pescara, Italy Department of Vascular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands PubMed articles Google scholar articles
Donatella Cibelli Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy PubMed articles Google scholar articles
Rosa Scurti Geriatric Medicine Unit, Pescara General Hospital, Pescara, Italy PubMed articles Google scholar articles
Antonella Frattari Intensive Care Unit, Pescara General Hospital, Pescara, Italy PubMed articles Google scholar articles
Ettore Porreca Department of Medical, Oral and Biotechnological Sciences, "G D'Annunzio" University, Chieti, Italy PubMed articles Google scholar articles
Antonio Abbate VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA PubMed articles Google scholar articles
Giustino Parruti Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy PubMed articles Google scholar articles

Correspondence to Dr Giustino Parruti, Infectious Diseases Unit, Pescara Hospital, Pescara 65124, Italy; parrutig{at}gmail.com

View Full Text

Citation

Potere N, Di Nisio M, Cibelli D, et al

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study

Annals of the Rheumatic Diseases 2021;80:1-2.

Publication history

Received June 5, 2020
Revised June 28, 2020
Accepted June 29, 2020
First published July 9, 2020.

Online issue publication

January 12, 2021

Article Versions

Previous version (9 July 2020).
You are viewing the most recent version of this article.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Copyright information

Read the full text or download the PDF:

Log in using your username and password